A

circRNA	Tag Name	% Identity	Alignment Length	Mismatches	Gap Openings	Tag Start	Tag End	circRNA Start	circRNA ENd	Upstream/Downstream
hsa_circ_0058058	HHFPT_162394_PTB_cluster- 13357_8_18_47	100.00	47	0	0	1	47	0	+512	Downstream
hsa_circ_0058058	HHFPT_162395_PTB_cluster- 13357_9_20_85	100.00	85	0	0	1	85	+734	+818	Downstream



Figure S1. PTBP1-induced circATIC inhibited tumor growth. A. The binding sites between PTBP1 and circATIC predicted by CircInteractome database. B. RT-qPCR confirmed the knockdown of circATIC by shRNAs.



Figure S2. CircATIC sponges miR-1247-5p. A. The binding sites between AGO2 and circATIC predicted by CircInteractome database. B. miRNAs predicted to bind with circATIC. C. miR-1247-5p expression in bladder cancer tissues compared to normal tissues according to TCGA database. D. The core binding sequence between circATIC and miR-1247-5p.



Figure S3. Bioinformatics analysis predicted target genes of miR-1247-5p. A. Starbase database showed that NPC1 expression was negatively correlated with miR-1247-5p expression in bladder cancer tissues. B. Starbase database showed that NPC1 was not dysregulated in bladder cancer tissues. C. Starbase database showed that TMEM8A expression was positively correlated with miR-1247-5p expression in bladder cancer tissues. D. Starbase database showed that TMEM8A was up-regulated in bladder cancer tissues (n=411) comparing to normal tissues (n=19).

circititi		Tag Na	me		% Identity	Alignmer Length	^{it} M	ismatch	es Gap Opening	Tag s Start	Tag End	circRNA Start	circRNA ENd	Upstream/Downstrea
nsa_circ_0058058	HPTLA_21972_LIN28A_	G17174_5_E	NST000004	43953_ATIC_5	atr_29 100.00	29		0	0	1	29	-402	-374	Upstream
Circular RNA	Tag Name		% Identity	Alignment Length	Mismatches	Gap Openings	Tag Star	t End	Circular Ci RNA I Start I	rcular RNA ENd				
nsa_circ_0058058	HHYLH_3621_LIN28_H	9_15045_33	100.00	33	0	0	1	33	140	172				
nsa_circ_0058058	HHYLV_1997_LIN28_V	5_15045_37	100.00	37	0	0	1	37	301	337				
isa_circ_0058058	HHYLV_1998_LIN28_V	5_15045_84	100.00	84	0	0	1	84	377	460	J			
NST00000375436	1	RCC2-202		ţ	Exon-13		† 3	UTR	77	1				
Transcript ID	T- T	Transcript	Name	T1. †	Binding Exon Exon-13		14 B	Binding R	egion	1	14- 1			
ENST00000474892		RCC2-203			Exon-2		E	xon						
franscript ID	1.	Transcript	Name	11	Binding Exon		11 8	Binding R	egion		11			
ENST00000375436	t	RCC2-202 RCC2-201		Ť	Exon-13		0	DS						
			F	(
log2(MAPK8 TPM) B = 0 B = 0 C = 4 B = 0 C = 4 C = 4 C = 6 C = 6 C = 6 C = 6 C = 7 C = 6 C = 7 C	ue = 0 .47			log2(MAPK9 TPM) 3 4 5 6 	alue = 0.00012 0.18									

A

Figure S4. circATIC/LIN28A complex binds to RCC2 and activate JNK. A. The binding site between LIN28A and ATIC pre-mRNA predicted by CircInteractome database. B. The binding site between LIN28A and circATIC predicted by CircInteractome database. C. The binding site between LIN28A and RCC2 transcript predicted by Starbase database. D-E. TCGA database predicted that RCC2 expression was significantly correlated with MAPK9 and MAPK8.



Figure S5. CircATIC promoted EMT and activated RCC2/JNK in DDP-resistant cells. A. EMT markers expression and RCC2/JNK expression in DDP-resistant cells. B. RTqPCR showed the expression of circATIC, miR-1247-5p and RCC2 in migrated cells. C. The IHC staining of EMT markers in xenograft subcutaneous nodules. D. The IHC staining of RCC2 and EMT markers in DDPR4 nodules.

Gene	Sequence (5'-3')	
circATIC	F: ACGCCAGTTAGCCTTGAAGC	R: CCTCCGGAAGCGACCAGATT
ATIC	F: CGGCTCTTCCACCACTGATT	R: GGCGTGACTGTTCACCTACA
GAPDH	F: CAAGGCTGAGAACGGGAAG	R: TGAAGACGCCAGTGGACTC
U6	F: CGCTTCGGCAGCACATATAC	R: TTCACGAATTTGCGTGTCAT
miR-1247-5p	F: CCCGTCCCGTTCGT	R: GTCCAGTTTTTTTTTTTTTTTTTCCG
miR-203a	F: CAGGTGAAATGTTTAGGACCA	R: GGTCCAGTTTTTTTTTTTTTTTTTTTTTTTTTT
miR-335	F: GCAGTCAAGAGCAATAACGA	R: CAGGTCCAGTTTTTTTTTTTTTTTTACA
miR-338-3p	F: GCAGTCCAGCATCAGTG	R: GGTCCAGTTTTTTTTTTTTTTTTTCAAC
miR-377	F: GCAGATCACACAAAGGCA	R: GTCCAGTTTTTTTTTTTTTTTTTACAAAAGT
miR-515-5p	F: CAGTTCTCCAAAAGAAAGCAC	R: GTCCAGTTTTTTTTTTTTTTTTTCAGAAAG
miR-605-3p	F: GCAGAGAAGGCACTATGAG	R: GGTCCAGTTTTTTTTTTTTTTTTTTTTTTAAATC
miR-125a-5p	F: CCCTGAGACCCTTTAACCT	R: GGTCCAGTTTTTTTTTTTTTTTTTCACA
miR-1301-3p	F: GCTGCCTGGGAGTGA	R: GGTCCAGTTTTTTTTTTTTTTTTGAAG
miR-1205	F: AGTCTGCAGGGTTTGCT	R: GGTCCAGTTTTTTTTTTTTTTTTTTTCTCA
miR-1299	F: CAGTTCTGGAATTCTGTGTGA	R: GTCCAGTTTTTTTTTTTTTTTTTTCCCT
miR-557	F: CGGGTGGGCCTTG	R: GGTCCAGTTTTTTTTTTTTTTTTAGAC
miR-619-3p	F: ACCTGGACATGTTTGTGC	R: CAGGTCCAGTTTTTTTTTTTTTTTTTACT
miR-619-5p	F: GCTGGGATTACAGGCATGA	R: TCCAGTTTTTTTTTTTTTTTTTGGCT
RCC2	F: GCGCACTCGCCAATTAAGAG	R: GCACAGAAAGGGCTGATCCT
PTBP1	F: AGCGCGTGAAGATCCTGTTC	R: CAGGGGTGAGTTGCCGTAG
LIN28A	F: CTTTTGCCAAAGCATCAACC3	R: GGGCTGTGGATCTCTTCCTC

Supplementary Table S1. List of primers

shRNA	Sequence $(5' - 3')$
shcirc-NC (shNC)	GIICICCGAACGIGICACGI
circATIC shRNA-1(shcirc-1)	GTTAGCCTTGAAGCCTTATTT
circATIC shRNA-2(shcirc-2)	GCCTTGAAGCCTTATTTAGTG
shNC	CAACAAGATGAAGAGCACCAA
shPTBP1	GCACAGAAAGGGCTGATCCT
circATIC WT	ATCTGGTCGCTTCCGGAGGGACTGCAAAAGCTCTCA
	GGGATGCTGGTCTGGCAGTCAGAGATGTCTCTGAGTT
	GACGGGATTTCCTGAAATGTTGGGGGGGACGTGTGAA
	AACTTTGCATCCTGCAGTCCATGCTGGAATCCTAGCT
	CGTAATATTCCAGAAGATAATGCTGACATGGCCAGAC
	TTGATTTCAATCTTATAAGAGTTG
circATIC Mut	ATCTGGTCGCTTCCGGAGGGACTGCAAAAGCTCTCA
	GGGATGCTGGTCTGGCAGTCAGAGATGTCTCTGAGTT
	CTGCCCATTTCCTGAAATGTTGGGGGGGACGTGTGAA
	AACTTTGCATCCTGCAGTCCATGCTGGAATCCTAGCT
	CGTAATATTCCAGAAGATAATGCTGACATGGCCAGAC
	TTGATTTCAATCTTATAAGAGTTG
RCC2 WT	TGCTCCCGGAGACTCCTCCGACTCCACACCTCTCGCG
	GCAGCTGTCATTTCCATGTGCACTGGGACGGGAAGT
	CAAACGAGGAATTTAAAAAAGCAAAAGTTGACCGA
	AGGTGCATTTTTGTTTAGACTCCCTGAGGT
RCC2 Mut	TGCTCCCGGAGACTCCTCCGACTCCACACCTCTCGCG
	GCAGCTGTCATTTCCATGTGCACTGCCTGCCCAAGTC
	AAACGAGGAATTTAAAAAAGCAAAAGTTGACCGAA
	GGTGCATTTTTGTTTAGACTCCCTGAGGT
oe-RCC2	NM_018715.4
miR-NC mimic	mircON mimic NC #22 (RiboBio, China)
miR-1247-5p mimic	mircON has-miR-1247-5p mimic (RiboBio, China)
5'Biotin ATIC pre-mRNA	GAAACAGTACAGCAAAGGCGTATCTCAGATGCCCTT
, i	GAGATATGGAATGAACCCACATCAGACCCCTGCCCA

Supplementary Table S2. Sequences of plasmids

	GCTGTACACACTG
shRCC2	CAACTCAGATGGGAAGTTCAT
shLIN28A-1	CCTGGTGGAGTATTCTGTATT
shLIN28A-2	GCACCAGAGTAAGCTGCACAT
Circ-NC/circ-WT/circ-	Synthesized by RiboBio
Mut1/circ-Mut2/circ-Mut3	

Supplementary Table S3. List of antibodies

Antibodies	Source (Identifier)	Application		
E-cadherin	Proteintech (20874-1-AP)	Western blot and IHC		
N-cadherin	Proteintech (22018-1-AP)	Western blot and IHC		
Vimentin	Cell Signaling Technology (#5741)	Western blot		
GST	Cell Signaling Technology (#2622)	TRAP		
AGO2	Cell Signaling Technology (#2897)	TRAP		
RCC2	Proteintech (16755-1-AP)	Western blot and IHC		
p-JNK	ZenBio (#381100)	Western blot		
GAPDH	Cell Signaling Technology (#5174)	Western blot and TRAP		
Ki67	Proteintech (27309-1-AP)	IHC		
PTBP1	Proteintech (12582-1-AP)	Western blot and ChIRP		
LIN28A	Proteintech (11724-1-AP)	RIP		